Back to top
more

BioNTech (BNTX)

(Delayed Data from NSDQ)

$87.21 USD

87.21
355,703

+0.50 (0.58%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $87.20 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?

by Zacks Equity Research

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

by Zacks Equity Research

To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.

Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump

by Zacks Equity Research

Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.

Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.

Pfizer (PFE) Stock Sinks on Weak 2024 View as COVID Sales Fall

by Zacks Equity Research

Pfizer's (PFE) shares decline almost 7% in response to the muted guidance for 2024. Revenues are expected to be in the range of $58.5 to $61.5 billion, while adjusted EPS is expected in the range of $2.05 to $2.25.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency Use

by Zacks Equity Research

Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Kinjel Shah headshot

Pfizer's (PFE) New Products May Drive Long-Term Sales Growth

by Kinjel Shah

Though Pfizer's (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is expected to drive long-term sales and profit growth.

Pfizer's (PFE) Q3 Loss Narrows, Sales Miss on COVID Slump

by Zacks Equity Research

Pfizer (PFE) reports mixed third-quarter 2023 results. It re-affirms its 2023 sales and earnings guidance provided earlier this month.

Pfizer's (PFE) Key Drugs to Drive Q3 Earnings Amid COVID Decline?

by Zacks Equity Research

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.

Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View

by Zacks Equity Research

Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.

Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Nu Holdings and Tyson Foods have been highlighted as Zacks Bull and Bear of the Day.

Pfizer's (PFE) Ulcerative Colitis Pill Etrasimod Gets FDA Nod

by Zacks Equity Research

The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.

Pfizer (PFE) Cuts 2023 Outlook as COVID Products' Demand Falls

by Zacks Equity Research

Pfizer (PFE) lowers its total revenue guidance for 2023 by $9 billion as sales from its COVID products, Comirnaty vaccine and Paxlovid pill decline.

Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio

by Zacks Equity Research

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.

Do Options Traders Know Something About BioNTech (BNTX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to BioNTech (BNTX) stock based on the movements in the options market lately.

Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab

by Zacks Equity Research

Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

by Zacks Equity Research

Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

by Zacks Equity Research

Pfizer, BioNTech, Moderna and Novavax are included in this Analyst Blog.

Kinjel Shah headshot

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

by Kinjel Shah

Pfizer (PFE)/ BioNTech (BNTX), and Moderna's (MRNA) updated mRNA vaccines are now approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age.

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

by Zacks Equity Research

Clinical study data shows Moderna's (MRNA) updated COVID-19 vaccine generates a robust immune response against newer circulating variants, including Pirola and Eris.

Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

by Zacks Equity Research

This growth in Novavax (NVAX) is likely due to the rising COVID-19 infection cases in the United States. Management claims its updated vaccine is effective against the newly emerged virus variants.